Background: While disclosure of cancer is routine in the United States, it is not in Japan. The primary goals of this investigation were to describe overseas Japanese patients' preferences for participation in decisions about cancer; to delineate patients' beliefs about how physicians should make cancer disclosure decisions; and to assess patients' attitudes about a advance directive for cancer disclosure.
INTRODUCTION
Advance directives are advocated as a means of extending patient autonomy to circumstances A N IMPORTANT CHALLENGE in medical care oc-when the individual is no longer competent to curs when patients' and their families' cul-designate his/her preferences for use of life-sustural beliefs about best health care practices dif-taining treatment and other medical therafer from the procedures their physicians are pies. 37 " 39 Given the diversity in cancer disclosure accustomed to following. 1 -8 These differences practices and patient preferences to know if afmay be particularly relevant when cancer is di-fected with cancer, Asai and others 40 ' 41 have proagnosed, an emotionally trying time for patient, posed and implemented in Japan an advance difamily, and physician alike. They can be espe-rective for cancer disclosure as a proactive means cially profound when patients and their physi-to guide a physician's cancer disclosure practices cians have different cultural backgrounds. 9 " 11 for individual patients. In his survey of new paDifferent approaches to disclosure of a cancer tients at an outpatient internal medicine clinic, diagnosis illustrate this tension. In most countries 76% (n = 228) thought that physicians should of the world, physicians do not routinely disclose routinely ask patients if they would want to know a diagnosis of cancer to their patients. 12 " 18 As in about a cancer diagnosis. 41 While Freedman 42 has many of these countries, Japanese physicians typ-suggested the approach of "offering truth" after ically have been taught to avoid candidly dis-cancer is diagnosed, to our knowledge no cornclosing bad news such as a cancer diagnosis to parable advance directive documents or techthe patient. 19 Recently, the merits and approaches niques have been used in the United States for to nondisclosure and disclosure of cancer in Japan determining patient preferences for disclosure have generated significant interest among the prior to establishing the cancer diagnosis, general population, physicians, medical ethicists,
The purposes of this research were: (1) to deand the government. 20 " 36 scribe overseas Japanese patients' preferences for When Japanese people come to the United communication and participation in medical deStates, they move from a country where nondis-cisions about cancer; (2) to delineate patients' beclosure predominates to one where disclosure is liefs about how physicians should make decisions nearly ubiquitous. As in other cultural groups in about whether and how to disclose a cancer dithe U.S., some Japanese are here by choice with agnosis to a patient; and (3) to assess patients' ata desire to be integrated into U.S. society. Others titudes about the use of an advanced directive for such as political refugees or those who are trans-cancer disclosure, ferred on temporary assignment by their companies, do not necessarily come by choice, nor are they necessarily interested in adopting U.S. customs. In the global economy, the number of peo-METHODS pie on temporary work assignments abroad such as Japanese employees and their families will
We conducted an ethnography of overseas continue to grow. In such circumstances when Japanese patients presenting for outpatient care cultural norms about cancer disclosure conflict, to the Japanese Family Health Program, an inithe issue of how to communicate with patients tiative designed to provide linguistically and culabout cancer becomes particularly pertinent.
rurally sensitive care to the population of Japan-ese people residing in Southeastern Michigan, quently conveyed according to their wishes. The The project was approved by the University of criterion of theoretical saturation was used as the Michigan Health Systems Institutional Review primary endpoint of data collection. 49 ' 50 Board. Through the process of reflexivity, we reThe data were analyzed using the process of viewed our personal and professional back-immersion/crystallization. 43 ' 51 We "immersed" grounds, and through this process sought to iden-ourselves in the data by reviewing the transcripts tify our own biases. 43 " 45 and other field notes multiple times until the maEligibility criteria required the participant to be jor themes "crystallized" out. We then went back an overseas Japanese patient who presented dur-to the text to assess the accuracy of the themes ing the study period for a comprehensive health and sub-themes. We synthesized from the data a maintenance examination (ningen dokku), or a pa-cohesive overview of the content and used illustient who needed diagnostic testing to rule out an trative quotes and metaphors generated by the illness such as lung, breast, cervical, stomach, or participants. We tabulated the responses to the colon cancer. The participants were interviewed questions asked of most or all the participants, at the time one or more cancer test(s) was (were) Because new questions were added in the course ordered in order to minimize the artificiality and of data collection, not all questions were asked of hypothetical nature of the inquiry.
all participants. Patient recruitment occurred in a community setting from 1 July 1995 until 31 December 1996. Fourteen months into the study, the clinical pro-RESULTS gram moved to a new site where data collection continued an additional four months. Patients Demographics were intentionally selected to obtain maximal FortHhree le met eligibility criteria. Of variation in patient gender and age distribution. 4 48 The interviews Preferred methods to receive results. Table 4 sumwere conducted after completing the patient's marizes patient's preferences for receiving results clinical examination. Their preferences were (letter, telephone, or in person), according to the recorded in the chart and the results were subse-result of the screening or diagnostic test; that is, Two reasons were commonly given for being told. First, many patients feel the need to make life plans. A second reason is to learn the details and implications of the illness. Those who did not desire disclosure at the medium and advanced stage fell into three areas: (1) wanted a family member to be told, (2) simply did not want to be told, and (3) couldn't answer the question.
Family member involvement. Most participants wanted family members involved when receiving results positive for cancer (Table 5) . In this circumstance, most of the male and female participants indicated their preference to receive notification of the need to schedule an appointment to discuss an abnormal result by mail or phone. They indicated they would come with their spouse to the appointment and learn the news together.
Exceptions occurred mostly among individuals who indicated their preference for disclosure of the diagnosis by stage, especially, for an advanced stage cancer. There were other exceptions as well. One male patient asked that his wife not be present at the time of disclosure as he preferred to disclose this information to her. A minority of the participating men stated that if they had cancer that they would want to be told, but they would not want their wives told if their wives had cancer.
There were also a minority of women who stated that they would want to be told if cancer was diagnosed in themselves, but that they would not want their husbands to be told if cancer was diagnosed. There was one couple for whom the wife indicated her preference to be told Virtually all participants indicated that in some circumstances it would be preferable for physicians to not disclose a cancer diagnosis to a patient. The reasons for not disclosing the information varied from person to person. No specific factors, such as age, gender, personality, and cancer stage, were agreed on to use in making a decision to disclose, or not disclose, the cancer diagnosis.
Reasons for nondisclosure or disclosure of cancer diagnosis. Among the varied reasons for withholding the cancer diagnosis was the use of deception with intent of motivating the patient to be cured, Some participants referred to the "mental" side of curing cancer and encouraged physicians to avoid causing psychological stress.
Participants also gave a series of reasons for disclosing cancer to the patient. One opinion was simply the aversion to not knowing. A male participant said, "I think for myself that knowing everything, the truth, is the best . . . Just the thought of thinking, I bet it is, I bet it is,' and men n ot being told anything is scary." Other less frequently raised factors included patients havm g particular religious beliefs and patients havm 8 a 8 ood understanding of science and, therefore, an ability to think objectively about the problem and its management. Personality. Patienf s personality had the most consistent support for use as a factor in determining whether to disclose the cancer diagnosis. That is, someone who has a "weak" personality should not be told. One woman explained, "For someone who worries too much, paradoxically, they become obsessed with only the illness, and it becomes difficult to treat the person... There was a man in my husband's company whose health was deteriorating, and he was worried that it was cancer. He couldn't play golf, and he couldn't bring food to his lips. I really think it is better not to tell someone like that."
When asked for advice on how to make a determination of who had a "weak" personality, some laughed as though that was something physicians were supposed to already know, while others held their breath and advised it was difficult to do. The most common advice was to talk to family members in order to get an assessment of the person's personality. One respondent illustrated, "I think personality is important. Since you won't know unless you're watching the person all the time, I can't help but feel that the family knows best." The circumstance of the patient having a strong personality was also addressed. One women said, "I think it is better to tell if it someone who is mentally strong and tough, who will take in the news for what it is, and make the best of it." The problem of relying on the patient's personality was also noted by a minority. One illustrative response by a man was, "I have my work face, and my home face, and there is no one who knows both of my selves. It is difficult to judge who knows my personality."
Age. Age elicited strong support as a criterion, but there were conflicting age cutoffs. Some felt that older people should not be told; others thought the elderly were more likely to accept the diagnosis well and should be told. For example, one male explained, I think younger people are shocked more than older people. I think that someone about the age of 90 recognizes that whether or not afflicted with cancer, that their time will come. Also, for someone who is 50 or 60 years of age, they can still work a lot and enjoy life, so I think telling them will allow them to enjoy the remainder of their lives.
Several of those supporting telling younger people were mothers with small children, who wanted to be able to plan for the care of their children after mother's death from cancer.
Gender. While most respondents felt gender was not important, six participants voiced opinions about the role of gender. These six responses indicated three conflicting rationales. First, some (male and female) participants indicated a belief that men should be told because they had important social responsibilities. Second, there was a belief that women should be told ambiguously because they overreact and think about too many contingencies. A third rationale was that men, in general, were less able to handle bad news than women were and, thus, it would be easier to tell women than men. Prognosis. As indicated above in patient preferences for conveying results, a worse prognosis is associated with a greater likelihood that the patient will not want the cancer diagnosis revealed (Fig. 2) . A number of participants reflected particularly about the circumstance of a terminal cancer. For example, one explained, If the patient is told 'terminal cancer' he or she wonders about death, and it just gets translated into untreatable... (pause) There is a fear of death, isn't there? I think the problem is how to soften that fear of death. If you don't do a good job softening the truth, because for someone with cure rate of 10% or less, someone with untreatable disease, I think just disclosing cancer is irresponsible . . . (pause) While I think there is movement in the direction of disclosure in Japan, I think this is largely a discussion of people with curable disease.
Patients who preferred disclosure varied with the stage of the cancer. The first subgroup, is male patients who prefer not to know if there is less than a 50% chance of cure. The second sub-group, female and male patients, prefer not to be told if there is terminal cancer.
Cancer type. Most patients stated that the cancer type (breast versus stomach versus colon, etc.) should not influence whether the diagnosis is disclosed. Of those who thought it should, they qualified their response that some cancers were more likely to be diagnosed in an early stage. Thus, considering stage, patients overwhelmingly felt that cancer type should not influence whether the patient should be told.
Participants' advice on deciding what to say. Partic-
ipants were asked to give advice on how doctors should decide the difficult issue of who ought to be told a cancer diagnosis. This generated a variety of responses. Among these was advice for using deception with intent of motivating the patient to be cured. One participant said, In order to have the best chance for cure, I think agreement can be elicited by using an eloquent expression. If you start treatment saying, "Even by starting treatment now, at best there is a 10% chance of cure," or you start treatment saying, "If you try really hard, I think there a 50% chance of cure." I think there is a very different outcome. It is OK to tell a lie if you have a good outcome.
These participants referred to the "mental side" of curing cancer and encourage physicians to avoid causing psychological stress. For example, they indicated that part of doctoring is giving the patient hope. This sentiment was expressed by one woman who advised,
In the case of a cancer that is 100% fatal, I don't want you to say, "There is 100% chance it is fatal. hopeless, I hope you will speak in a way that gives at least a little hope.
Acceptability of advance directives for cancer disclosure
Patients were asked whether they believed the use of a questionnaire and advanced discussion was an acceptable way of approaching patients who have a screening or diagnostic test for a possible cancer diagnosis (Table 6 ). This line of questioning generated four responses.
The vast majority of participants voiced enthusiastic support for advance directive use. One woman posited, "When asked my preference for disclosure while healthy, as you are doing, an honest preference comes out. So I think asking is best. When asked, 'Do you want to know? Do you not want to know' I think everyone will ask you to do it." A male participant echoed her thoughts and said, "I think it is really important to conduct a survey and ask for people's opinions about whether they want to be told they have cancer. I think especially in Japan that things are changing. There are people with the same opinion as me, and people with different opinions, so I hope you will refer to this and use it in your treatment."
The other three responses were more cautious, and one was even very negative. Some were concerned that raising the issue caused uneasiness, especially for someone who presented with symptoms. One woman explained, "If you spring this discussion on me when I am ill, it makes me wonder whether or not I have cancer." Another concern with an advanced directive for disclosure was impact on trusting the doctor. One man explained, "If you start out by saying that your preference is not to be told, the trustworthiness of the discussion thereafter drops." The third response reflected resentment that doctors would even consider not disclosing the truth. One man expressed his concern that this approach was a waste of time. He shared his belief that patients ought to be told the truth about their health regardless of the problem. He believed there was an inordinate obsession with cancer and a lack of adequate discussion in general about illness.
DISCUSSION

Communication and participation in medical decision about cancer
These participants' beliefs regarding many aspects of communication about cancer test results differ from standard approaches in the United States. No participant consensus on one best way to convey results to patients was identified, but tively these ought to determine whether the pathe vast majority of participants preferred to get tient should be told, no consistent agreement was normal results in writing rather than personally found about what factors are most important and from the physician in the office or by telephone, how those factors should influence decisions. This contrasts with similar research done in the These participants believe that the cancer paUnited States by Lind et al. 52 who found that fe-tient's personality, or ability to handle bad news, male patients preferred getting normal mammo-is a crucial consideration, though they also indigram results by phone call. Still, most patients cate other factors such as age, gender, etc., to be with an abnormality in both our study and the relevant as well. Most believe that the spouse is lind study preferred to learn of an abnormal re-the best judge of the patient's ability to handle suit in person.
this information. Interestingly, physicians have Most patients expressed a preference to be told identified the same factors as relevant for delibthe details of their illness if an early stage cancer eration about cancer disclosure and end-of-life was diagnosed. The number with a clear prefer-decision making. 30 ' 55 ence for disclosure declined as the prognosis Many have criticized Japanese physicians' neworsened, a trend supported by research con-gleet to disclose cancer and, hence, for not pracducted in Japan. 41/53 These beliefs also parallel the ticing informed consent and respecting patient trend for Japanese physicians to disclose less in-autonomy. However, these data suggest that formation about cancer as the prognosis wors-Japanese physicians and patients share similar ens. 30 ' 54 thinking about cancer disclosure. Concordant The patients who did not want to be told if can-views include, first, the belief that some people cer was diagnosed consistently identified their exist to whom a cancer diagnosis should not be spouses as the individuals to whom they wished disclosed and, second, the belief that contextual the information to be conveyed. All participants issues such as the patient's personality, age, genwere married and in their third to fifth decades der, cancer stage, and other factors are crucial in of life. Because it is uncommon for an older par-decisions about whether to disclose a cancer dient or other family members besides children to agnosis. This suggests that Japanese physicians' live with expatriate families in the United States, behaviors are based in extant, social norms and for most participants the only plausible substitute not just in the cultural norms of Japanese medidecision-maker would have been the spouse. It is cine, conceivable that their preferences might differ in Japan, though previous research has identified AtHtudes about m advanced directive for similar patterns of decision making by family, es-cmcer disdosure pecially the spouse, in Japan. 19 ' 30 ' 31 As illustrated in the movie Daibyounin, physi-" . , ,. , , , . .. , cian and family decision makers are in a Patient beliefs about how to disclose cancer quandary if the patient's preferences are unThese participants' responses do not consis-known. Once the patient is told, no retreat may tenth/ support respect for patient autonomy and be made. This very complex circumstance is in cancer disclosure. Regardless of their own pref-dire need of simplification, erences, most participants believe that under cer- Figure 3 illustrates how the advance directive tain circumstances some patients, including those for disclosure could circumvent the complex syswho are competent, should not be told a cancer tern of decision making about disclosure. At time diagnosis. This implies they believe there should to, the patient can direct disclosure to others such be flexibility for cancer disclosure decision mak-as the family or oneself. After cancer is diagnosed ing, because some prefer disclosure, others do at time ti, the information is disclosed at time t 2 not, and no predictors are known of which peo-to the person or others as directed by the patient, pie would fit into each pattern.
In the event the patient prefers not to be told, or Figure 3 graphically summarizes patients' ad-does not want to make an advance directive for vice to weigh a variety of factors when deciding disclosure, decision making proceeds in the whether to disclose cancer. While most agreed a usual, complicated fashion with the physician series of factors should be weighed in decision and family weighing a series of factors a, b, c ... making about cancer disclosure, and cumula-n, as necessary for determining sufficient reasons to disclose or not disclose the information to the patient. Most participants support asking patients in advance their preferences for disclosure when a screening or diagnostic test for cancer is ordered. Both personal discussion with the physician or in writing through a written document was acceptable. Most patients did not feel that asking them for their preferences made them uncomfortable. Rather, it was reassuring that they would be given information in a manner driven by their own preferences.
Since the implementation of advance directives for cancer disclosure in the Japanese Family Health Program, two Japanese patients have been diagnosed with cancer. Through an oral advance directive, both indicated an a priori preference to know all the details of their care. Among those patients indicating a preference to not be told a cancer diagnosis, none have been identified with cancer.
When a newly identified cancer patient asks in advance for non-disclosure, Western bioethics and Japanese values will clash. If the U.S. clinician-investigator (M.F.) is to live up to the patient's advance directive, he will have to deceive the patient. Steeped in a tradition of informed decision making and cancer disclosure, the mere thought is discomforting, but provides an inkling of how uncomfortable Japanese physicians might feel about disclosing cancer. U.S. clinicians have not been trained to deceive the patient. Japanese physicians, who have been trained to protect patients by deceiving them, must feel similarly uncomfortable about disclosure.
The advance directive for cancer disclosure may provide a practical mechanism for communicating with patients with cancer. Unfortunately, the standard advance directive is far from foolproof. In the SUPPORT study, patient advance directives were not found to have a clinically relevant impact. 56 Furthermore, while the number of people who have obtained directives cific cultural group. Despite broad advocacy by is growing, most Americans do not have one and medical ethicists for cancer disclosure in the their physicians often don't even know the pa-United States, subgroups of patients in the United tient has completed one. 57 " 61 States are opposed to being told. Blackhall et al. 62 There may be other pitfalls of using an advance examined differences in preference for disclosure directive for cancer disclosure as well. An oral ad-among (n = 200) patients 65 years of age and vance directive, in particular, can most easily be older who were living in Southern California. The respected if the patient is seen exclusively by the participants who favored cancer disclosure varphysician with whom it was discussed. The re-ied significantly: African American (88%), Euroquirement to obtain informed consent before pro-pean American (87%), Mexican American (65%), viding chemotherapy protocols, radiation treat-and Korean American (47%). Those favoring disments, and surgery has been codified in law. closure of a terminal prognosis were even fewer, What are the implications for following the pa-African American (63%), European American tient's preferences when it conflicts with the law? (69%), Mexican American (48%), and Korean Finally, the current data are not necessarily American (35%). Thus, even in the United States generalizable to all overseas Japanese people, where disclosure is a near-ubiquitous approach, Most of the participants were of child bearing or patient preferences for disclosure and participachild rearing age. The paucity of retired individ-tion in decision making vary. 63 The lack of conuals in the overseas population of the region pre-sistent beliefs among patients about the approeluded their enrollment in the study. Further-priateness of disclosure, and the consistently more, most participants have financial security identified trend in this and other studies for more and health insurance, although these attributes patients preferring not to be told the cancer diare not unusual for the Japanese population, agnosis as the prognosis grows worse may raise which has universal healthcare coverage and a particular problems for palliative care efforts, low unemployment rate.
To innovate is to renew, alter, or introduce new methods or devices. Use of advance directives in the United States have previously been reserved CONCLUSIONS exclusively for patients who are incompetent to make decisions, as it is assumed that all compeWhile some Japanese patients supported deci-tent patients either want to or should be informed sion making reflecting patient autonomy and can-and participate in their medical decisions. 64 ' 65 cer disclosure for themselves or others, many si-Medical ethicists do not agree on whether a culmultaneously articulated beliefs that decisions rurally-based preference not to know information should be situational and not driven by a hard and not to participate in decision making should and fast rule of cancer disclosure. Most felt there trump the hard-earned, but now routine, right to were circumstances when cancer should not be be informed and participate in decisions. Until disclosed. While there was not absolute agree-consensus is reached, an advance directive for ment on the specific factors to consider nor agree-cancer disclosure offers clinicians a modest, inment on how to weigh them, they do articulate a novative tool to facilitate patient participation in multifactorial process of decision making that is decision making, consistent with processes identified in data collected from Japanese physicians. Thus, while a Japanese physician approach of nondisclosure of APPENDIX cancer conflicts with Western bioethics notion of patient autonomy and informed consent there is Questionnaire patient support for these actions some of the tame, ** but not all of the time. Physicians need to be wary During your health check today, we will order that they are not so addicted to deceiving that one or more cancer diagnostic or screening test(s). they can never tell the truth. An advance direc-The purpose of a screening test is to identify distive for cancer disclosure offers a potential means ease early when it is curable. Most cancer screenfor guiding which approach to disclosure should ing tests are negative. Still, screening tests can be followed.
find both early stage, middle stage and advanced The notion of an advance directive for cancer stage cancers. Diagnostic tests are done to look disclosure may have importance beyond this spe-for disease when the patient has symptoms.
As you may know, doctors in Japan often do not tell patients when cancer is found. But in the United States, doctors almost always tell patients the truth. Given this cultural difference, we would like to learn of your preference in advance of finding the results so we can follow your preference.
You are receiving tests for . 
